This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Short Report
Manya Mirchandani
Imperial College London
Corresponding Author
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Declarations:
Declarations
- The author has confirmed that a statement listing potential conflicts of interest or lack thereof is included in the text.
Ivermectin has become a controversial potential medicine for COVID-19. Some early studies suggested clinical benefits in treatment and prevention of infection. However, the body of evidence includes studies of varying quality. Furthermore, some trials have now been identified as potentially fraudulent.
We present a sub-group analysis, to assess the effects of stratifying by trial quality on the overall results. The stratification is based on the Cochrane Risk of Bias measures (RoB 2) and analysis of raw data where possible.
The results suggest that the significant effect of ivermectin on survival was dependent on largely poor quality and potentially fraudulent studies. This highlights the need for rigorous quality assessments, the need for authors to share patient level data and efforts to continue to avoid publication bias for registered studies. These steps are vital to facilitate accurate conclusions on any clinical treatment.
Keywords
ivermectin, COVID-19, SARS-CoV-2, bias, medical fraud
Figure 1
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 25 Oct, 2021
Community comments: 9
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Infectious Diseases
Learn more about our company.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Short Report
Manya Mirchandani
Imperial College London
Corresponding Author
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 25 Oct, 2021
Community comments: 9
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Infectious Diseases
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Declarations:
Declarations
- The author has confirmed that a statement listing potential conflicts of interest or lack thereof is included in the text.
Ivermectin has become a controversial potential medicine for COVID-19. Some early studies suggested clinical benefits in treatment and prevention of infection. However, the body of evidence includes studies of varying quality. Furthermore, some trials have now been identified as potentially fraudulent.
We present a sub-group analysis, to assess the effects of stratifying by trial quality on the overall results. The stratification is based on the Cochrane Risk of Bias measures (RoB 2) and analysis of raw data where possible.
The results suggest that the significant effect of ivermectin on survival was dependent on largely poor quality and potentially fraudulent studies. This highlights the need for rigorous quality assessments, the need for authors to share patient level data and efforts to continue to avoid publication bias for registered studies. These steps are vital to facilitate accurate conclusions on any clinical treatment.
Figure 1
Loading...